Related Experiment Video
Updated: May 3, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro
Samir M Abdelmagid1, Joyce Y Belcher1, Fouad M Moussa2
1Department of Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, Ohio.
Abstract:
We have previously identified osteoactivin (OA), encoded by Gpnmb, as an osteogenic factor that stimulates osteoblast differentiation in vitro. To elucidate the importance of OA in osteogenesis, we characterized the skeletal phenotype of a mouse model, DBA/2J (D2J) with a loss-of-function mutation in Gpnmb. Microtomography of D2J mice showed decreased trabecular mass, compared to that in wild-type mice [DBA/2J-Gpnmb(+)/SjJ (D2J/Gpnmb(+))]. Serum analysis showed decreases in OA and the bone-formation markers alkaline phosphatase and osteocalcin in D2J mice. Although D2J mice showed decreased osteoid and mineralization surfaces, their osteoblasts were increased in number, compared to D2J/Gpnmb(+) mice. We then examined the ability of D2J osteoblasts to differentiate in culture, where their differentiation and function were decreased, as evidenced by low alkaline phosphatase activity and matrix mineralization. Quantitative RT-PCR analyses confirmed the decreased expression of differentiation markers in D2J osteoblasts. In vitro, D2J osteoblasts proliferated and survived significantly less, compared to D2J/Gpnmb(+) osteoblasts. Next, we investigated whether mutant OA protein induces endoplasmic reticulum stress in D2J osteoblasts. Neither endoplasmic reticulum stress markers nor endoplasmic reticulum ultrastructure were altered in D2J osteoblasts. Finally, we assessed underlying mechanisms that might alter proliferation of D2J osteoblasts. Interestingly, TGF-β receptors and Smad-2/3 phosphorylation were up-regulated in D2J osteoblasts, suggesting that OA contributes to TGF-β signaling. These data confirm the anabolic role of OA in postnatal bone formation.
Insights
Osteoactivin (OA) is crucial for bone formation. Mice lacking functional OA exhibit reduced bone mass and impaired osteoblast function, highlighting OA's anabolic role in skeletal development.
Area of Science:
- Bone Biology and Skeletal Development
- Molecular Endocrinology
- Cellular and Molecular Physiology
Background:
- Osteoactivin (OA), encoded by Gpnmb, was previously identified as an osteogenic factor promoting osteoblast differentiation in vitro.
- Understanding the in vivo role of OA in postnatal bone formation is essential for elucidating its contribution to skeletal health.
Purpose of the Study:
- To investigate the skeletal phenotype of mice with a loss-of-function mutation in Gpnmb, the gene encoding OA.
- To determine the impact of OA deficiency on osteoblast differentiation, proliferation, and function in vivo and in vitro.
- To explore the underlying molecular mechanisms, including TGF-β signaling, affected by OA deficiency.
Main Methods:
- Characterization of the skeletal phenotype of DBA/2J mice with a Gpnmb loss-of-function mutation using microtomography.
- Serum analysis of OA and bone formation markers (alkaline phosphatase, osteocalcin).
- In vitro assessment of osteoblast differentiation, proliferation, and function, including gene expression analysis and examination of endoplasmic reticulum stress markers.
Main Results:
- Mice with Gpnmb mutation exhibited significantly decreased trabecular bone mass and reduced serum levels of OA, alkaline phosphatase, and osteocalcin.
- Osteoblasts from mutant mice showed impaired differentiation, reduced alkaline phosphatase activity, and decreased matrix mineralization in vitro.
- Despite increased osteoblast numbers in vivo, mutant osteoblasts displayed reduced proliferation and survival, with up-regulation of TGF-β receptors and Smad-2/3 phosphorylation.
Conclusions:
- The study confirms the critical anabolic role of osteoactivin (OA) in postnatal bone formation.
- OA deficiency leads to impaired osteoblast function and reduced bone mass, mediated in part by alterations in TGF-β signaling.
- These findings underscore OA's importance in maintaining skeletal integrity and suggest potential therapeutic targets for bone diseases.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:40Bone Remodeling
01:16In-vitro Mutagenesis
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...